New Evidence to Assess the Efficacy and Safety of DOACs for the Treatment of NVAF

You are leaving Medscape Education

Cancel Continue

CME & Education

Kirchhof P, Benussi S, Kotecha D, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
Cubillos L, Haddad A, Kuznik A, et al. Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med. 2014;7:441-448.
Benjamin EJ, Muntner P, Alonso A, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56-e66.
Lip GY, Nieuwlatt R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263-272.
Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731-2738.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019. doi: 10.1016/j.jacc.2019.01.011. [Epub ahead of print].
Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013;170:215-220.
Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-1974.
Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014;35:224-232.
Michniewicz E, Mlodawska E, Lopatowska P, et al. Patients with atrial fibrillation and coronary artery disease - Double trouble. Adv Med Sci. 2018;63:30-35.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-1912.
DeWilde WJ, Janssen PW, Verheugt FW, et al. Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. J Am Coll Cardiol. 2014;64:1270-1280.
Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185-1193.
Dewilde WJ, Oirbans T, Vergeugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107-1115.
Lip GY, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154:1121-1201.
Lip GY, Collet JP, Haude M, et al; ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019;21:192-193.
Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2018;138:527-536.
Mahmood M, Lip GY. Management of atrial fibrillation: easy as ABC. Minerva Med. 2019;110:27-34.
Shah A, Shewale A, Hayes CJ, et al. Cost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patients. Stroke. 2016;47:1555-1561.
Lopez-Lopez JA, Sterne JA, Thom HH, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.
Mendoza-Sanchez J, Silva F, Rangel L, et al. Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis. PLoS ONE. 2018;13:e0196361.
Hernandez I, Smith KJ, Zhang Y. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thromb Res. 2017;150:123-130.
Lanas F, Castro C, Vallejos C, et al. Latin American Clinical Epidemiology Network Series - Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile. J Clin Epidemiol. 2017;86:75-83.
Alegret JM, Vinolas X, Arias MA, et al. New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. Int J Med Sci. 2014;11:680-684.
Baluci KG, Balci MM, Canpolat U, et al. Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. Anatol J Cardiol. 2016;16:474-481.
Gwyn JC, Thomas MR, Kirchoof P. Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint. Eur Heart J Cardiovasc Pharmacother. 2017;3:157-162.
Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial . J Am Coll Cardiol. 2015;65:1619-1629.
Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423-2434.
Cannon CP, Bhatt DL, Oldgren J, et al; RE-DUAL PCI Steering Committee and Invetigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513-1524.
Golwala HB, Cannon CP, Steg PG, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018;39:1726-1735.
Matsumura-Nakano Y, Shizuta S, Komasa A, et al; OAC-ALONE Study Investigators. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019;139:604-616.
Vranckx P, Lewalter T, Valgimigli M, et al. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial. Am Heart J. 2018;196:105-112.
Lopes RD, Vora AN, Liaw D, et al. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. Am Heart J. 2018;200:17-23.
Valgimigli M, Bueno H, Byrne RA, et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213-260.
Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective-2016 Update. Circ Cardiovasc Interv. 2016;9:e004395.
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330-1393.
Lopes RD, Heizer G, Aronson R, et al; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019. doi: 10.1056/NEJMoa1817083. [Epub ahead of print].

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Christopher B. Granger, MD

Professor of Medicine
Director
Cardiac Intensive Care Unit
Duke University Medical Center
Durham, North Carolina, United States

Disclosures

Disclosure: Christopher B. Granger, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie, Inc.; AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; Espero BioPharma; Janssen Pharmaceuticals; Medtronic, Inc.; Merck & Co., Inc.; Novo Nordisk; Novartis Pharmaceutical Company; Pfizer, Inc.; Roche Diagnostics
Received grants for clinical research from: AKROS Pharma, Inc.; Apple; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Duke Clinical Research Institute; GlaxoSmithKline; Janssen Pharmaceuticals; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.

Gregory Y.H. Lip, MD

Price-Evans Chair of Cardiovascular Medicine
University of Liverpool
Director, Liverpool Centre for Cardiovascular Science
Liverpool Heart & Chest Hospital Centre for Cardiovascular Sciences
Liverpool, United Kingdom

Disclosures

Disclosure: Gregory Y.H. Lip, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi-Sankyo, Inc.; Janssen Pharmaceuticals; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Verseon
Served as a speaker or a member of a speakers bureau for: Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi-Sankyo, Inc.; Medtronic, Inc.; Pfizer, Inc.

Roxana Mehran, MD

Professor of Medicine (Cardiology)
Icahn School of Medicine
Mount Sinai
New York, New York, United States

Disclosures

Disclosure: Roxana Mehran, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ABIOMED; Abbott, Inc.; Boston Scientific; Regeneron Pharmaceuticals, Inc.; Roivant Sciences, Inc.; Sanofi; Siemens AG; Spectranetics; Philips Healthcare; The Medicines Company; Volcano Corporation
Received grants for clinical research from: AstraZeneca; Bayer AG; Beth Israel Deaconess; Bristol-Myers Squibb Company; CSL Behring; Daiichi Sankyo, Inc.; Eli Lilly and Company; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; OrbusNeich; Sanofi
Owns stock, stock options, or bonds from: Claret Medical, Inc.; Elixir Medical
Other: Bristol Myers Squibb Company; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Watermark Research

Renato D. Lopes, MD, PhD

Professor of Medicine
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina, United States

Disclosures

Disclosure: Renato D. Lopes, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Boehringer Ingleheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Pfizer, Inc.; Portola Pharmaceuticals, Inc.
Received grants for clinical research from: Amgen, Inc.; Bayer AG; Boehringer Ingleheim Pharmaceuticals Corporation; Bristol-Myers Squibb Company; GlaxoSmithKline; Pfizer, Inc.; Portola Pharmaceuticals, Inc.; Sanofi-Aventis

Editor

Anne M. Sendaydiego, PharmD

Scientific Director, WebMD Global, LLC

Disclosures

Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

processing....

Legendas em português

« Return to: New Evidence to Assess the Efficacy and Safety of DOACs for the Treatment of NVAF

Download Slides

Print